Enterprise Value
8.994M
Cash
3.84M
Avg Qtr Burn
-6.133M
Short % of Float
1.32%
Insider Ownership
28.29%
Institutional Own.
42.71%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BF-RhodoLED® XL combo w/ Ameluz® Details Actinic keratosis | Approved Quarterly sales | |
XEPI (ozenoxacin) Details Impetigo | Approved Quarterly sales | |
Ameluz (aminolevulinic acid hydrochloride) Details BCC (basal cell carcinoma), AK (actinic keratosis) | Approved Quarterly sales | |
Ameluz® - PDT (3 tubes) Details Actinic keratosis | PDUFA Approval decision | |
Ameluz® Details Actinic keratosis | Phase 3 Data readout | |
BF-RhodoLED® XL combo w/ Ameluz® Details Actinic keratosis, Acne | Phase 2 Data readout |